ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Exploring the interconnection between PANoptosis and chronic inflammatory diseases: identifying key targets and therapeutic strategies for periodontitis and ulcerative colitis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Periodontitis (PD) and ulcerative colitis (UC) are chronic inflammatory diseases that may share underlying molecular mechanisms, potentially mediated by PANoptosis, which integrates pyroptosis, apoptosis, and necroptosis. Understanding their interaction could unveil novel therapeutic targets. This study aimed to identify key targets and pathways linked to PD and UC, explore the interaction between PANoptosis-related genes and PD-UC-related genes, and predict potential therapeutic targets and drugs for PD-UC. In this study, we acquired datasets from the GEO database, including GSE16134 for PD and GSE87466 for UC. Disease-related targets were identified through differential expression analysis and weighted gene co-expression network analysis. These targets were compared with PANoptosis-related targets and used to form protein-protein interaction networks. Enrichment analyses, such as GO and KEGG, were conducted to investigate the biological significance. Core genes were pinpointed utilizing LASSO and SVM-RFE algorithms, and their expressions were verified in an experimental PD and DSS-induced UC mouse model and single-cell RNA sequencing. A ceRNA network was established, and potential drugs targeting core genes were predicted. Molecular docking simulations were performed to determine binding interactions. As a result, a total of 107 intersected genes were identified, with BAG3, LYN, and APOE recognized as core targets. These genes were significantly associated with immunological processes and inflammatory pathways, as evidenced by enrichment analyses. Histological and molecular validation in mice confirmed their differential expression in PD and UC. Single-cell RNA sequencing revealed cell-type-specific expression of core genes, with Lyn enriched in myeloid cells and Apoe in fibroblasts. A ceRNA network highlighted regulatory interactions, while drug prediction pinpointed potential therapeutic agents for LYN and APOE. In conclusion, the study identifies core genes and their molecular networks bridging PANoptosis with PD and UC, underscoring the potential of BAG3, LYN, and APOE as therapeutic targets. These discoveries establish PANoptosis as a novel therapeutic axis for chronic inflammatory comorbidities, bridging the gap between oral and intestinal mucosal immunity.
Indexed as
Identifiers
40600991What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.